Results for this period
First quarter1 April 2026 to 30 June 2026ConsolidatedIFRSThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Higher sales in both businesses, higher sales and profit due to the yen's depreciation, increased gross profit from higher sales, and the absence of the license consideration recorded in the previous fiscal year and the one-time costs of Elevate contributed to the increase in profit. On the other hand, a deterioration in the cost ratio due to U.S. tariffs, costs related to Swan EndoSurgical,Inc., and valuation losses on foreign exchange derivatives contributed to the decrease in profit.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | ¥240,400 million (YoY +16.4%) |
| Operating profit | ¥28,951 million (YoY +74.4%) |
| Ordinary income | ¥27,562 million (YoY +63.2%) |
| Profit attributable to owners of the parent | ¥19,102 million (YoY +112.5%) |
| Net income per share | ¥17.76 |
| Equity ratio | End of the current fiscal period 49 / End of previous period 52.8 |
| Total assets | ¥1,526,474 million |
| Net assets | ¥747,902 million |
| Cash flows from operating activities | ¥14,334 million |
| Cash flows from investing activities | ¥-64,245 million |
| Cash flows from financing activities | ¥-20,983 million |
| Cash and cash equivalents at end of period | ¥118,545 million |
| Full-year earnings forecast | Net Sales value Limit 1,076,000 / Downside floor 1,055,000 / yoy_pct Limit 6.5 / Downside floor 4.4 / Operating profit value Limit 155,500 / Downside floor 136,500 / yoy_pct Limit 60.1 / Downside floor 40.5 / Ordinary income value Limit 149,500 / Downside floor 130,500 / yoy_pct Limit 59.1 / Downside floor 38.8 / Net income value Limit 109,000 / Downside floor 95,500 / yoy_pct Limit 59.9 / Downside floor 40.1 |
| Revision to Earnings Forecast | Net Sales No revision / Operating profit No revision / Ordinary income No revision / Net income No revision |
| Annual Dividend Forecast | ¥30 → ¥30（0.0%） |
| Segment revenue | Gastrointestinal endoscopy solutions ¥168,448 million (YoY +21.2%), Surgical intervention ¥71,923 million (YoY +6.7%) |
| Segment profit | Gastrointestinal endoscopy solutions ¥38,646 million (YoY +113.0%), Surgical intervention ¥-2,404 million |
| Regional sales | Japan Current fiscal year ¥23,071 million / Prior-year period ¥23,026 million / North America Current fiscal year ¥101,096 million / Prior-year period ¥81,569 million / Europe Current fiscal year ¥65,973 million / Prior-year period ¥55,269 million / China Current fiscal year ¥16,419 million / Prior-year period ¥16,947 million / Asia and Oceania Current fiscal year ¥25,089 million / Prior-year period ¥22,192 million / Other Current fiscal year ¥8,752 million / Prior-year period ¥7,509 million |
| Depreciation and amortization | ¥17,308 million |
| Impairment loss | ¥274 million |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement Not disclosed |
| Changes in the scope of consolidation | New 1 / Name of newly added company BioProtect Ltd. / Excluded 0 / Excluded Company Name Not disclosed |
| Material subsequent events | Regarding the claim for a refund of U.S. tariffs, part of the claimed amount was received after the end of the first-quarter consolidated accounting period. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable Yes / Subject person Analysts and institutional investors |
| Issued Shares at Period-End | 1,114,485,700 |
| Treasury Shares at Period-End | 51,666,048 |
| Factors Behind Changes in Business Performance | Higher sales in both businesses, higher sales and profit due to the yen's depreciation, increased gross profit from higher sales, and the absence of the license consideration recorded in the previous fiscal year and the one-time costs of Elevate contributed to the increase in profit. On the other hand, a deterioration in the cost ratio due to U.S. tariffs, costs related to Swan EndoSurgical,Inc., and valuation losses on foreign exchange derivatives contributed to the decrease in profit. |
Items this document does not state (5)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Both the Gastrointestinal Endoscopy Solutions business and the Surgical Intervention business reported higher sales. The yen's depreciation generated positive factors of ¥23,231 million in net sales and ¥4,377 million in operating profit. Profit was also boosted by higher gross profit from increased sales and the absence of the approximately ¥6 billion consideration recorded in the previous fiscal year under the agreement with Evident, as well as the one-time costs of the Elevate quality assurance and regulatory compliance project. On the other hand, a deterioration in the cost ratio due to U.S. tariffs, costs related to Swan EndoSurgical,Inc., and valuation losses on foreign exchange derivatives were negative factors for profit.